Full Press Release Details
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled“Dosage Regimens for Benzgalantamine.”
The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer’s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company’s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease.
“This newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “These method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value in the U.S. market.”
The issuance of this patent further advances Alpha Cognition’s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.
This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available atwww.sedar.comand the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available atwww.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.